Category Archives: Psoriasis

Novartis AG (NOVN) won U.S. approval for the first in a new line of psoriasis drugs that aim to better treat the itchy, sometimes debilitating skin condition.

The Food and Drug Administration cleared the treatment to be called Cosentyx. The medicine, also known as secukinumab, is predicted to top $1 billion in sales by 2020 and will compete with other biologic drugs including AbbVie Inc. (ABBV)s No. 1 seller, Humira, and Amgen Inc. (AMGN)s best-selling Enbrel. The therapy was backed in November by European Commission health regulators.

About 7.5 million Americans have psoriasis, which is an autoimmune disease that can cause raised, red patches on the skin that are covered in dead skin cells, according to the National Psoriasis Foundation. The new type of drugs called interleukin inhibitors block interaction with the IL-17A receptor, which triggers the inflammatory response that plays a role in the disease, the FDA said.

The FDAs approval of Cosentyx signifies a turning point for psoriasis patients, who can now benefit from the first and only approved treatment targeting the IL-17 pathway, David Epstein, division head of Novartis Pharmaceuticals, said in a statement.

Similar drugs are in development at Eli Lilly & Co. (LLY) and in a partnership of Amgen and AstraZeneca Plc. (AZN) The new therapies work faster and are expected to be more effective for the most serious patients.

Cosentyx is administered as an injection under the skin. It is intended for patients who are candidates for systemic therapy, treatment using substances that travel through the bloodstream, and ultraviolet light therapy, or a combination of both, the FDA said today in a statement.

The FDAs approval was based on four clinical trials that studied secukinumab against a placebo and found more patients on the drug had clear or almost clear skin, the agency said.

Novartis, based in Basel, Switzerland, also studied secukinumab against Thousand Oaks, California-based Amgens Enbrel and said it worked significantly better to clear the skin. The latest study pitting secukinumab against Johnson & Johnson (JNJ)s Stelara showed Novartiss drug worked better, the company said in a Dec. 12 statement.

Novartiss drug may generate $1.1 billion in annual sales in 2020, according to the average of seven analysts estimates compiled by Bloomberg. AbbVies Humira had an estimated $12.6 billion in sales in 2014 while Amgen and Pfizer Inc. are expected to report about $8.4 billion in Enbrel revenue.

Older treatments such as Enbrel and Humira block a protein called TNF that signals the body to create inflammation. Stelara targets proteins known as IL-12 and IL-23, while secukinumab goes after IL-17A, which only recently has been linked to psoriasis.

Read the original post:
Novartis Wins U.S. Approval for First of New Psoriasis Drugs

Psoriasis ,Ayurvedic view and Best Ayurvedic Treatment
Dr. Amit Dutta #39;s :: AYUR - SUDHA :: Advanced Ayurveda Skin Treatment centre is propagating all common to chronic Skin related disorders with authentic Ayurvedic , Herbal medicines and ...

By: AYUR -SUDHA :: Ayurvedic Skin Centre

See the original post:
Psoriasis ,Ayurvedic view and Best Ayurvedic Treatment - Video

Psoriasis Revolution Review - Pathway to a Psoriasis-Free Life?
Psoriasis Revolution System and Review - http://prominentoffers.com/skin-care-recommendations/psoriasis-revolution-review/ Are you dealing with chronic psori...

By: ProminentOffers

Read the original:
Psoriasis Revolution Review - Pathway to a Psoriasis-Free Life? - Video

Psoriasis Man Choreographed Dance Rehearsal
Psoriasis is NOT Contagious. But because of the lack of awareness, people shun us because they think we are. 1 in 100 Singaporeans suffer from an incurable a...

By: The Psoriasis Man Ray Chua

See the original post here:
Psoriasis Man Choreographed Dance Rehearsal - Video

Homeopathic Palmar Psoriasis treatment
Homeopathic Palmar Psoriasis treatement in India Psoriasis treatement Best Psoriasis treatement in Indore Best Psoriasis treatement in India Palmar Psoriasis...

By: Dr AK Dwivedi

Originally posted here:
Homeopathic Palmar Psoriasis treatment - Video

MRT Testimonial Eva having Hyperthyroidism/Goitre / Psoriasis (Updated)
MRT Testimonial Eva having Hyperthyroidism/Goitre / Psoriasis (Updated) From TKC Intensive Training Class 2.0 (3rd - 4th Jan 2015)

By: Keith KJ Leong

Read the original here:
MRT Testimonial Eva having Hyperthyroidism/Goitre / & Psoriasis (Updated) - Video

Psoriasis Remedies - The Fast Psoriasis Treatment, Psoriasis cure
Psoriasis Remedies - The Fast Psoriasis Treatment, Psoriasis cure The five main types of psoriasis are plaque, guttate, inverse, pustular, and erythrodermic....

By: Bala Guru

Excerpt from:
Psoriasis Remedies - The Fast Psoriasis Treatment, Psoriasis cure - Video

Psoriasis Diet Diary Day in the Life #1
This video shows a vague day in the life of me. 1. Wake up, drink water (the first of 3-5 litres throughout the day) 2. Get breakfast: Banana Date Smoothie...

By: Jon Maddison

Original post:
Psoriasis Diet Diary Day in the Life #1 - Video

Solucin Cura Problemas de la Piel: acne, caida del cabello,psoriasis,manchas,quemaduras
Solucion Definitiva tratamiento para la Piel :acne,Acn Hipertrofico (Nariz), Acn rosasea, caida del cabello, manos humedas (Hiperhidrosis),Mano seca ( Dishidrosis), ICTIOSIS, manchas oscuras...

By: Mundo Emprendedor TV

Originally posted here:
Solucin Cura Problemas de la Piel: acne, caida del cabello,psoriasis,manchas,quemaduras - Video

Case Western Reserve scientists have taken a huge leap toward identifying root causes of psoriasis, an inflammatory skin condition affecting 125 million people around the world. Of the roughly 50,000 proteins in the human body, researchers have zeroed in on four that appear most likely to contribute this chronic disease. The findings, published this month in Molecular & Cellular Proteomics, dramatically advance efforts to understand how psoriasis develops -- and, in turn, how to stop it.

"Psoriasis affects 2 to 3 percent of the population worldwide," said senior author Nicole L. Ward, PhD, associate professor of dermatology and neurosciences, Case Western Reserve University School of Medicine. "The underlying cause of psoriasis remains unknown, and the specific signals that trigger disease onset are still being investigated. There currently is no cure."

Ward's lab is focused on studying the pathogenesis of the disease and its co-morbidities, including heart attack and stroke. Her group is actively working to identify new molecules key to the disease process that could become potential drug targets. Ward has a personal interest in this research -- her father suffers from psoriasis.

Psoriasis is an autoimmune skin disease characterized by well-demarcated areas of red, raised and scaly skin next to areas of normal-appearing skin. Autoimmune diseases are those where the body launches an abnormal immune response against its own tissues. Another complication of psoriasis is joint involvement, a condition termed psoriatic arthritis.

Ward and her team first narrowed their pool of potential culprits to about 1,280 proteins that are differentially regulated in the condition. From there, they focused on five that stood out either because of their high prevalence in human psoriasis or their prominence in other studies relating to human psoriasis tissue. Ward's lab team took skin tissue samples from her well-established psoriasis transgenic mouse model, called the KC-Tie2 mouse, and compared it to skin tissue samples of normal mice. Her lab collaborated with Mark R. Chance, PhD, director of the Center for Proteomics and Bioinformatics, CWRU School of Medicine, and his team at the center to identify new proteins that were differentially regulated in the skin tissue of psoriasis mice compared to the skin tissue of healthy mice.

To ensure that the proteins identified in the mouse were important to human psoriasis, her team then examined human psoriasis skin cells, known as keratinocytes, and human psoriasis skin tissue samples to confirm the increased presence of these proteins in human disease. In the skin of the psoriasis mice, investigators first identified increases in stefin A1 (342.4-fold increased; called cystatin A in humans); slc25a5 (46.2-fold increased); serpinb3b (35.6-fold increased; called serpinB1 in humans) and KLK6 (4.7-fold increased). The team found no increases of the Rab18 protein in skin tissue of the mice, and so ruled it out as a psoriasis-generating culprit. Investigators then confirmed the increased presence of the Serpinb3b, KLK6, Stefin A1 and Slc25a5 proteins in human lesional psoriasis skin tissue, and human lesional psoriasis skin cells compared to healthy control skin tissue and skin cells.

"We were interested in looking for the increased presence of these proteins, not just in the psoriasis-like skin inflammation of the mouse, but more importantly, we needed to know how the increased presence of these proteins translated to human psoriasis," Ward said. "So we took the information we discovered in the mouse model and went back to the patients and confirmed the increase in these proteins in their lesional psoriasis skin tissue. We are really focused on, and enthusiastic about, our ability to perform successfully translational bench-to bedside-and-back-again psoriasis research here at CWRU School of Medicine Department of Dermatology and the Murdough Family Center for Psoriasis at University Hospitals Case Medical Center. It's what we excel at and what we love to do."

The next step in pursuing this line of research for Ward's team will be uncovering the role and significance of each of these proteins in the progression of psoriasis. Determining the individual contributions of each protein will help provide strategic therapeutic targets to change the course of a patient's psoriasis or, at the very least, provide a better understanding of how a change in the regulation of these proteins contributes to skin inflammation and psoriatic disease.

"We are always looking for novel targets or new insight into disease progression, remission or susceptibility," Ward said. "It's all about the patients. Even though what we are doing at the bench seems focused on mouse, the ultimate goal is to improve patient care and quality of life for patients."

Story Source:

Continue reading here:
Proteins likely to trigger psoriasis identified